Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

10
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
10
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

22
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
22
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

14
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
14
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

13
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
13
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

18
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
18
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

14
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
14

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness of Acceptance and Commitment Therapy (ACT) for the Management of Postsurgical Pain: A Randomized Controlled Trial (SPINE-ACT Study).

European journal of pain (London, England)·2026
Same author

Dual disorders: an overview.

Irish journal of psychological medicine·2026
Same author

Integrated treatment approaches for co-occurring mental health and substance use disorders: findings from a survey of European healthcare providers.

Irish journal of psychological medicine·2026
Same author

Soy isoflavones for the treatment of cocaine use disorder: an open-label pilot study.

Adicciones·2026
Same author

PRISM-5 update: Adaptation and validation of the Spanish version interview for dual diagnosis assessment based on DSM-5 criteria.

Spanish journal of psychiatry and mental health·2025
Same author

Predictive performance for alcohol use disorder of polygenic scores based on the general addiction risk factor and problematic alcohol use.

Drug and alcohol dependence·2025

Related Experiment Video

Updated: Feb 18, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.3K

Pharmacogenetics of Methadone Response.

Francina Fonseca1,2,3, Marta Torrens4,5,6

  • 1Institut de Neuropsiquiatria i Addiccions, Hospital del Mar, Passeig Marítim 25-29, 08003, Barcelona, Spain.

Molecular Diagnosis & Therapy
|November 24, 2017
PubMed
Summary

Genetic factors influence methadone maintenance treatment (MMT) effectiveness for opioid use disorder. Understanding these genetic variations can help personalize MMT dosages and reduce adverse events for better patient outcomes.

More Related Videos

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
09:54

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Published on: March 8, 2020

5.7K
A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

15.8K

Related Experiment Videos

Last Updated: Feb 18, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.3K
Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
09:54

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Published on: March 8, 2020

5.7K
A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

15.8K

Area of Science:

  • Pharmacogenetics
  • Clinical Pharmacology
  • Addiction Medicine

Background:

  • Methadone maintenance treatment (MMT) is effective for opioid use disorder, but patient responses vary significantly.
  • The impact of methadone pharmacodynamics and pharmacokinetics, particularly genetic influences, on MMT outcomes remains debated.
  • Current MMT dosing (60-100 mg/day) lacks clear plasma concentration targets for treatment success.

Purpose of the Study:

  • To review evidence on how genetic factors influence pharmacokinetic and pharmacodynamic aspects of MMT.
  • To analyze the genetic contribution to severe adverse events like respiratory depression and ventricular arrhythmia during methadone treatment.
  • To explore the potential of pharmacogenetics in personalizing MMT.

Main Methods:

  • Literature review of studies investigating genetic influences on methadone response.
  • Analysis of genetic impact on pharmacokinetic (drug metabolism and transport) and pharmacodynamic (drug effect) pathways.
  • Examination of genetic associations with adverse events and treatment efficacy.

Main Results:

  • MMT outcomes are shaped by a complex interplay of environmental, drug-induced, and genetic factors.
  • Pharmacokinetic genetic variability can be managed by adjusting methadone dosage.
  • Pharmacodynamic insights may guide opioid selection, but patient phenotype remains crucial.

Conclusions:

  • Pharmacogenetic studies offer a promising avenue for individualizing MMT based on a patient's genetic profile.
  • Tailoring medication and dosage according to genetic background can optimize treatment outcomes and mitigate risks of adverse events.
  • Personalized medicine approaches in MMT are essential for improving patient care in opioid use disorder.